

Ramon Colomer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5455397/publications.pdf>

Version: 2024-02-01

258
papers

10,831
citations

³¹⁹⁷⁶
53
h-index

³⁶⁰²⁸
97
g-index

271
all docs

271
docs citations

271
times ranked

12679
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. <i>Lancet</i> , The, 2013, 381, 805-816.	13.7	1,664
2	Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. <i>Annals of Oncology</i> , 2008, 19, 420-432.	1.2	410
3	Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. <i>European Respiratory Journal</i> , 2011, 37, 624-631.	6.7	304
4	Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 10715-10720.	7.1	297
5	Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. <i>Science</i> , 1990, 249, 1552-1555.	12.6	289
6	International conference on the healthy effect of virgin olive oil. <i>European Journal of Clinical Investigation</i> , 2005, 35, 421-424.	3.4	248
7	Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 1557.	7.1	242
8	n-3 Fatty acids, cancer and cachexia: a systematic review of the literature. <i>British Journal of Nutrition</i> , 2007, 97, 823-831.	2.3	219
9	Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin [®] , [©]) in breast cancer cells with Her-2/neu oncogene amplification. <i>Annals of Oncology</i> , 2005, 16, 359-371.	1.2	197
10	Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. <i>European Journal of Cancer</i> , 2019, 109, 21-27.	2.8	188
11	Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. <i>Cell Proliferation</i> , 2008, 41, 59-85.	5.3	160
12	Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis. <i>Journal of Clinical Oncology</i> , 1998, 16, 2065-2069.	1.6	155
13	Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin [®] , [©]) in HER2-overexpressing breast cancer cells. <i>BMC Cancer</i> , 2007, 7, 80.	2.6	154
14	Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. <i>Annals of Oncology</i> , 2018, 29, 646-653.	1.2	150
15	Endocrine Responsiveness and Tailoring Adjuvant Therapy for Postmenopausal Lymph Node-Negative Breast Cancer: A Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1054-1065.	6.3	138
16	CCR5 Expression Influences the Progression of Human Breast Cancer in a p53-dependent Manner. <i>Journal of Experimental Medicine</i> , 2003, 198, 1381-1389.	8.5	129
17	Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cells. <i>European Journal of Cancer</i> , 2001, 37, 402-413.	2.8	124
18	Improving Treatment of Chemotherapy-Induced Neutropenic Fever by Administration of Colony-Stimulating Factors. <i>Journal of the National Cancer Institute</i> , 1995, 87, 803-808.	6.3	122

#	ARTICLE	IF	CITATIONS
19	Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. <i>Clinical Cancer Research</i> , 2000, 6, 2356-62.	7.0	120
20	Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. <i>Cancer</i> , 1995, 75, 2147-2152.	4.1	116
21	A Single-Nucleotide Polymorphism in the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor Letrozole in Advanced Breast Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 811-816.	7.0	113
22	Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992, 89, 2287-2291.	7.1	110
23	Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. <i>Annals of Oncology</i> , 2012, 23, 625-631.	1.2	106
24	Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. <i>Cancer</i> , 1989, 64, 1674-1681.	4.1	103
25	Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity. <i>International Journal of Cancer</i> , 2005, 115, 19-35.	5.1	100
26	Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75. <i>Breast Cancer Research and Treatment</i> , 2008, 109, 471-479.	2.5	98
27	An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review). <i>International Journal of Molecular Medicine</i> , 2007, 20, 3-10.	4.0	96
28	Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases. <i>Breast Cancer Research and Treatment</i> , 1989, 13, 123-133.	2.5	94
29	Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever. <i>Cancer</i> , 1999, 85, 213-219.	4.1	94
30	When should we order a next generation sequencing test in a patient with cancer?. <i>EClinicalMedicine</i> , 2020, 25, 100487.	7.1	94
31	Mediterranean diet, olive oil and cancer. <i>Clinical and Translational Oncology</i> , 2006, 8, 15-21.	2.4	93
32	Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. <i>Annals of Oncology</i> , 2004, 15, 1749-1759.	1.2	90
33	erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. <i>British Journal of Cancer</i> , 1994, 70, 819-825.	6.4	87
34	Novel Inhibitors of Fatty Acid Synthase with Anticancer Activity. <i>Clinical Cancer Research</i> , 2009, 15, 7608-7615.	7.0	85
35	Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer.. <i>Journal of Clinical Oncology</i> , 1997, 15, 3178-3184.	1.6	84
36	Exogenous supplementation with ω -3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6n-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells. <i>European Journal of Cancer Prevention</i> , 2005, 14, 263-270.	1.3	84

#	ARTICLE	IF	CITATIONS
37	Protein array technology to detect HER2 (erbB-2)-induced cytokine signature™ in breast cancer. <i>European Journal of Cancer</i> , 2007, 43, 1117-1124.	2.8	83
38	Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain. <i>Annals of Oncology</i> , 2004, 15, 201-206.	1.2	80
39	Strategies to design clinical studies to identify predictive biomarkers in cancer research. <i>Cancer Treatment Reviews</i> , 2017, 53, 79-97.	7.7	80
40	A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines. <i>Breast Cancer Research</i> , 2011, 13, R131.	5.0	75
41	Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. <i>Clinical and Translational Oncology</i> , 2011, 13, 179-184.	2.4	75
42	Inhibition of Tumor-associated Fatty Acid Synthase Hyperactivity Induces Synergistic Chemosensitization of HER-2/neu-Overexpressing Human Breast Cancer Cells to Docetaxel (taxotere). <i>Breast Cancer Research and Treatment</i> , 2004, 84, 183-195.	2.5	71
43	Population-based incidence and survival of gastrointestinal stromal tumours (GIST) in Girona, Spain. <i>European Journal of Cancer</i> , 2007, 43, 144-148.	2.8	69
44	Synergistic Interaction Between Vinorelbine and Gamma-Linolenic Acid in Breast Cancer Cells. <i>Breast Cancer Research and Treatment</i> , 2002, 72, 203-219.	2.5	68
45	HER2 (erbB-2)-targeted effects of the ω -3 polyunsaturated. Fatty acid ω -linolenic acid (ALA; 18:3n-3) in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail". <i>Clinical and Translational Oncology</i> , 2006, 8, 812-820.	2.4	66
46	Targeting Fatty Acid Synthase: Potential for Therapeutic Intervention in Her-2/neu-Overexpressing Breast Cancer. <i>Drug News and Perspectives</i> , 2005, 18, 375.	1.5	66
47	BRCA1 and acetyl-CoA carboxylase: The metabolic syndrome of breast cancer. <i>Molecular Carcinogenesis</i> , 2008, 47, 157-163.	2.7	65
48	Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. <i>Lancet Oncology</i> , The, 2021, 22, 85-97.	10.7	64
49	Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids?. <i>Medical Hypotheses</i> , 2005, 64, 342-349.	1.5	62
50	Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells. <i>International Journal of Cancer</i> , 2015, 136, 2078-2090.	5.1	60
51	Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma. <i>British Journal of Cancer</i> , 1997, 76, 1215-1220.	6.4	59
52	New Synthetic Inhibitors of Fatty Acid Synthase with Anticancer Activity. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 5013-5023.	6.4	57
53	Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. <i>Clinical and Translational Oncology</i> , 2018, 20, 815-826.	2.4	57
54	Natural Polyphenols and their Synthetic Analogs as Emerging Anticancer Agents. <i>Current Drug Targets</i> , 2016, 18, 147-159.	2.1	55

#	ARTICLE	IF	CITATIONS
55	Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization.. Journal of Clinical Oncology, 1998, 16, 1538-1546.	1.6	53
56	Circulating CA 15-3 antigen levels in non-mammary malignancies. British Journal of Cancer, 1989, 59, 283-286.	6.4	50
57	Long-Term Survival in Advanced Ovarian Cancer after Cytoreduction and Chemotherapy Treatment. Gynecologic Oncology, 1994, 53, 27-32.	1.4	49
58	Trastuzumab Plus Tamoxifen: Anti-Proliferative and Molecular Interactions in Breast Carcinoma. Breast Cancer Research and Treatment, 2004, 86, 125-137.	2.5	47
59	In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer. Nature Communications, 2018, 9, 3501.	12.8	45
60	Herceptin: From the Bench to the Clinic. Cancer Investigation, 2001, 19, 49-56.	1.3	44
61	Interstitial pneumonitis after oxaliplatin treatment in colorectal cancer. Clinical and Translational Oncology, 2005, 7, 515-517.	2.4	44
62	A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer. Pancreatology, 2020, 20, 254-264.	1.1	44
63	Essentiality of fatty acid synthase in the 2D to anchorage-independent growth transition in transforming cells. Nature Communications, 2019, 10, 5011.	12.8	43
64	Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement. Oncologist, 2019, 24, 603-611.	3.7	43
65	Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells. Oncotarget, 2017, 8, 11600-11613.	1.8	43
66	Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: Relationship to lipid peroxidation and HER-2/neu expression. Oncology Reports, 2004, 11, 1241-52.	2.6	43
67	EGF Prevents the Neuroendocrine Differentiation of LNCaP Cells Induced By Serum Deprivation: The Modulator Role of P13K/Akt. Neoplasia, 2007, 9, 614-624.	5.3	42
68	Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). Annals of Oncology, 2010, 21, 195-198.	1.2	41
69	Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB. International Journal of Oncology, 2004, 24, 591-608.	3.3	41
70	It Is Not Time to Stop Progesterone Receptor Testing in Breast Cancer. Journal of Clinical Oncology, 2005, 23, 3868-3869.	1.6	40
71	Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma. Clinical and Translational Oncology, 2008, 10, 367-371.	2.4	39
72	Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (TykerbA®) in human breast carcinoma cells. Annals of Oncology, 2008, 19, 1097-1109.	1.2	39

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------

73	Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to		
----	--	--	--

#	ARTICLE	IF	CITATIONS
91	Dietary fatty acids regulate the activation status of Her-2/neu (c-erbB-2) oncogene in breast cancer cells. <i>Annals of Oncology</i> , 2004, 15, 1719-1721.	1.2	25
92	Doxorubicin and paclitaxel in advanced breast carcinoma. <i>Cancer</i> , 2000, 89, 2169-2175.	4.1	24
93	Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells. <i>Oncology Reports</i> , 2007, 18, 973.	2.6	24
94	Inhibition of fatty acid synthase-dependent neoplastic lipogenesis as the mechanism of α -linolenic acid-induced toxicity to tumor cells: an extension to Nwankwo's hypothesis. <i>Medical Hypotheses</i> , 2005, 64, 337-341.	1.5	23
95	Antimicrobial cyclic decapeptides with anticancer activity. <i>Peptides</i> , 2010, 31, 2017-2026.	2.4	23
96	Psychometric properties of the Perform Questionnaire: a brief scale for assessing patient perceptions of fatigue in cancer. <i>Supportive Care in Cancer</i> , 2011, 19, 657-666.	2.2	23
97	A new role for circulating T follicular helper cells in humoral response to anti-PD-1 therapy. , 2020, 8, e001187.		23
98	α -6 Polyunsaturated fatty acid α -linolenic acid (18:3n-6) is a selective estrogen-response modulator in human breast cancer cells: α -Linolenic acid antagonizes estrogen receptor-dependent transcriptional activity, transcriptionally represses estrogen receptor expression and synergistically enhances tamoxifen and ICI 182,780 (Faslodex) efficacy in human breast cancer cells. <i>International Journal of Cancer</i> , 2004, 109, 949-954.	5.1	22
99	FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1. <i>Breast Cancer Research</i> , 2021, 23, 21.	5.0	22
100	Usefulness of antibiotic-lock technique in management of oncology patients with uncomplicated bacteremia related to tunneled catheters. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2005, 24, 291-293.	2.9	21
101	Olive Oil in Cancer Prevention and Progression. <i>Nutrition Reviews</i> , 2006, 64, S40-S52.	5.8	21
102	Predictors of unknown cancer in patients with ischemic stroke. <i>Journal of Neuro-Oncology</i> , 2018, 137, 551-557.	2.9	21
103	Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial. <i>Breast Cancer Research</i> , 2020, 22, 124.	5.0	21
104	Brain metastases from breast cancer may respond to endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 1988, 12, 83-86.	2.5	20
105	A cytotoxic ribonuclease reduces the expression level of P-glycoprotein in multidrug-resistant cell lines. <i>Investigational New Drugs</i> , 2012, 30, 880-888.	2.6	19
106	Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines. <i>Clinical and Translational Oncology</i> , 2022, 24, 483-494.	2.4	19
107	Prognostic Value of Cytosolic p53 Protein in Breast Cancer. <i>Tumor Biology</i> , 2001, 22, 337-344.	1.8	18
108	Cranial CT scan in transient global amnesia. <i>Acta Neurologica Scandinavica</i> , 1986, 73, 298-301.	2.1	18

#	ARTICLE	IF	CITATIONS
109	Development of a New Questionnaire to Assess Patient Perceptions of Cancer-Related Fatigue: Item Generation and Item Reduction. <i>Value in Health</i> , 2009, 12, 130-138.	0.3	18
110	Skeletal muscle and solitary bone metastases from malignant melanoma: multimodality imaging and oncological outcome. <i>Melanoma Research</i> , 2018, 28, 562-570.	1.2	18
111	Phase II, 3-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results. <i>Journal of Clinical Oncology</i> , 2004, 22, 544-544.	1.6	18
112	Biweekly vinorelbine and gemcitabine: a phase I dose-finding study in patients with advanced solid tumors. <i>Annals of Oncology</i> , 2003, 14, 783-787.	1.2	17
113	Initially metastatic breast carcinoma has a distinct disease pattern but an equivalent outcome compared with recurrent metastatic breast carcinoma. <i>Cancer</i> , 2004, 100, 1833-1842.	4.1	17
114	Giacomo Castelvetro's salads. Anti-HER2 oncogene nutraceuticals since the 17th century?. <i>Clinical and Translational Oncology</i> , 2008, 10, 30-34.	2.4	17
115	Nivolumab-induced thyroid dysfunction in patients with lung cancer. <i>Endocrinología, Diabetes Y Nutrición</i> , 2019, 66, 26-34.	0.3	17
116	Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant Basal-HER2 subtype of breast cancer. <i>Oncotarget</i> , 2015, 6, 7104-7122.	1.8	17
117	Emotional Distress in Cancer Patients During the First Wave of the COVID-19 Pandemic. <i>Frontiers in Psychology</i> , 2021, 12, 755965.	2.1	17
118	Serum Ca 15.3 Levels in Patients with Non-Tumoral Diseases, and Establishment of a Threshold for Tumoral Activity. Results in 1219 Patients. <i>International Journal of Biological Markers</i> , 1986, 1, 159-160.	1.8	16
119	Validation of the 2001 St Gallen Risk Categories for Node-Negative Breast Cancer Using a Database From the Spanish Breast Cancer Research Group (GEICAM). <i>Journal of Clinical Oncology</i> , 2004, 22, 961-962.	1.6	16
120	Î‰-6 polyunsaturated fatty acid Î³-linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: Relationship to lipid peroxidation and HER-2/neu expression. <i>Oncology Reports</i> , 2004, 11, 1241.	2.6	16
121	What is the best schedule for administration of gemcitabine-taxane?. <i>Cancer Treatment Reviews</i> , 2005, 31, S23-S28.	7.7	16
122	Obesity, fatty acid synthase, and cancer: serendipity or forgotten causal linkage?. <i>Molecular Genetics and Metabolism</i> , 2005, 84, 293-295.	1.1	16
123	Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma. <i>Clinical and Translational Oncology</i> , 2011, 13, 636-651.	2.4	16
124	Advanced breast cancer clinical nursing curriculum: review and recommendations. <i>Clinical and Translational Oncology</i> , 2017, 19, 251-260.	2.4	16
125	Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition. <i>Breast Cancer Research</i> , 2019, 21, 69.	5.0	16
126	Her-2/neu-induced "Cytokine Signature" in Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2008, 617, 311-319.	1.6	16

#	ARTICLE	IF	CITATIONS
127	CA 15.3: early results of a new breast cancer marker. <i>Anticancer Research</i> , 1986, 6, 683-4.	1.1	16
128	Effects of a high olive oil diet on the clinical behavior and histopathological features of rat DMBA-induced mammary tumors compared with a high corn oil diet. <i>International Journal of Oncology</i> , 2002, 21, 745-53.	3.3	16
129	Mitomycin-C and Vinblastine in Advanced Breast Cancer. <i>Oncology</i> , 1989, 46, 137-142.	1.9	15
130	Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole. <i>Clinical and Translational Oncology</i> , 2006, 8, 193-199.	2.4	15
131	Pharmacological blockade of Fatty Acid Synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin [®]) by transcriptionally inhibiting $\hat{\epsilon}$ HER2 super-expression [™] occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells. <i>International Journal of Oncology</i> , 2007, 31, 769.	3.3	15
132	Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). <i>Clinical and Translational Oncology</i> , 2009, 11, 363-375.	2.4	15
133	Safety and Oncological Outcomes of Bevacizumab Therapy in Patients With Advanced Colorectal Cancer and Self-expandable Metal Stents. <i>Clinical Colorectal Cancer</i> , 2019, 18, e287-e293.	2.3	15
134	Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours. <i>Clinical and Translational Oncology</i> , 2021, 23, 1529-1541.	2.4	15
135	High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor ⁺ positive metastatic breast cancer: A confirmatory prospective study. <i>Cancer</i> , 2007, 110, 2178-2185.	4.1	14
136	Novel chemotherapy approaches in chemoradiation protocols. <i>Gynecologic Oncology</i> , 2008, 110, S45-S48.	1.4	14
137	Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: The importance of scheduling. <i>International Journal of Oncology</i> , 0, , .	3.3	14
138	Critically short telomeres and toxicity of chemotherapy in early breast cancer. <i>Oncotarget</i> , 2017, 8, 21472-21482.	1.8	14
139	Creatine transporter deficiency in two adult patients with static encephalopathy. <i>Journal of Inherited Metabolic Disease</i> , 2009, 32, 91-96.	3.6	13
140	Membrane disruption, but not metabolic rewiring, is the key mechanism of anticancer-action of FASN-inhibitors: a multi-omics analysis in ovarian cancer. <i>Scientific Reports</i> , 2020, 10, 14877.	3.3	13
141	Final development and validation of the BOMET-QoL questionnaire for assessing quality of life in patients with malignant bone disease due to neoplasia. <i>Journal of Medical Economics</i> , 2007, 10, 27-39.	2.1	12
142	Targeting cytoskeleton reorganisation as antimetastatic treatment. <i>Clinical and Translational Oncology</i> , 2010, 12, 662-669.	2.4	12
143	Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey. <i>Clinical and Translational Oncology</i> , 2013, 15, 477-483.	2.4	12
144	Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer patients. <i>Journal of Clinical Oncology</i> , 2004, 22, 507-507.	1.6	12

#	ARTICLE	IF	CITATIONS
145	Correlation between HER2/neu overexpression/amplification and clinicopathologic parameters in advanced gastric cancer (AGC) patients (pts): A prospective study. <i>Journal of Clinical Oncology</i> , 2006, 24, 4089-4089.	1.6	12
146	Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever. <i>Cancer</i> , 1999, 85, 213-219.	4.1	11
147	Recall Reaction of a Severe Local Peripheral Neuropathy After Paclitaxel Extravasation. <i>Journal of the National Cancer Institute</i> , 1996, 88, 1320-1320.	6.3	10
148	Biweekly gemcitabine plus vinorelbine in first-line metastatic breast cancer: efficacy and correlation with HER2 extracellular domain. <i>Clinical and Translational Oncology</i> , 2006, 8, 896-902.	2.4	10
149	Olive Oil in Cancer Prevention and Progression. <i>Nutrition Reviews</i> , 2006, 64, 40-52.	5.8	10
150	Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 351-358.	2.5	10
151	3D Assessment of Lymph Nodes vs. RECIST 1.1. <i>Academic Radiology</i> , 2011, 18, 391-394.	2.5	10
152	The Pharmacological or Genetic Blockade of Endogenous De Novo Fatty Acid Synthesis Does Not Increase the Uptake of Exogenous Lipids in Ovarian Cancer Cells. <i>Frontiers in Oncology</i> , 2021, 11, 610885.	2.8	10
153	Primary aortic sarcoma with widespread vascular embolic metastases. <i>European Journal of Internal Medicine</i> , 2003, 14, 258-261.	2.2	9
154	Gemcitabine in Combination with Paclitaxel for the Treatment of Metastatic Breast Cancer. <i>Women's Health</i> , 2005, 1, 323-329.	1.5	9
155	Usefulness of the PERFORM questionnaire to measure fatigue in cancer patients with anemia: a prospective, observational study. <i>Supportive Care in Cancer</i> , 2013, 21, 3039-3049.	2.2	9
156	The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival. <i>International Journal of Oncology</i> , 2005, 26, 1507-15.	3.3	9
157	The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair. <i>Cancers</i> , 2022, 14, 2950.	3.7	9
158	p53 Expression in Locally Advanced Pharyngeal Squamous Cell Carcinoma. <i>JAMA Otolaryngology</i> , 1999, 125, 1356.	1.2	8
159	High-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma. <i>Cancer</i> , 2001, 92, 2508-2516.	4.1	8
160	Modulation of EGFR and neu expression by n-6 and n-9 high-fat diets in experimental mammary adenocarcinomas. <i>Oncology Reports</i> , 2003, 10, 1417.	2.6	8
161	BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer. <i>Cancers</i> , 2022, 14, 2596.	3.7	8
162	Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer. <i>Clinical and Translational Oncology</i> , 2008, 10, 52-57.	2.4	7

#	ARTICLE	IF	CITATIONS
163	Circulating CA 15.3 levels in breast cancer. Our present experience. International Journal of Biological Markers, 1986, 1, 89-92.	1.8	7
164	Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial. Seminars in Oncology, 2000, 27, 20-4.	2.2	7
165	A Phase II Study of Sequential Docetaxel Followed by Doxorubicin/Cyclophosphamide as First-Line Chemotherapy For Metastatic Breast Cancer. Clinical Breast Cancer, 2003, 4, 286-291.	2.4	6
166	Recomendación para la determinación de HER2 en cáncer de mama. Consenso nacional de la Sociedad Española de Anatomía Patológica (SEAP) y de la Sociedad Española de Oncología Médica (SEOM). Revista Espanola De Patologia, 2009, 42, 3-16.	0.2	6
167	Consenso de la Sociedad Española de Anatomía Patológica (SEAP) y de la Sociedad Española de Oncología Médica (SEOM) sobre la determinación de HER2 en el carcinoma gástrico. Revista Espanola De Patologia, 2011, 44, 32-48.	0.2	6
168	In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours. British Journal of Cancer, 2013, 108, 1298-1305.	6.4	6
169	P2.02-027 Are Inflammatory Markers Predictive of Nivolumab Efficacy in Advanced Non-Small-Cell Lung Cancer (NSCLC)?. Journal of Thoracic Oncology, 2017, 12, S2108-S2109.	1.1	6
170	Real-world treatment in patients with HER2+ metastatic breast cancer. Breast Cancer Research and Treatment, 2018, 168, 197-205.	2.5	6
171	Phase I/II trial of capecitabine and gefitinib in patients with advanced colorectal cancer after failure of first-line therapy. Journal of Clinical Oncology, 2005, 23, 3176-3176.	1.6	6
172	Serum CA 15.3 levels in patients with non-tumoral diseases, and establishment of a threshold for tumoral activity. Results in 1219 patients. International Journal of Biological Markers, 1986, 1, 159-60.	1.8	6
173	The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival. International Journal of Oncology, 2005, 26, 1507.	3.3	5
174	Gemcitabine plus nab-paclitaxel versus modified FOLFIRINOX as first line chemotherapy in metastatic pancreatic cancer: A comparison of toxicity and survival. Annals of Oncology, 2018, 29, v46.	1.2	5
175	A Systemic Inflammation Response Index Could be a Predictive Factor for mFOLFIRINOX in Metastatic Pancreatic Cancer. Pancreas, 2019, 48, e45-e47.	1.1	5
176	Regulation of estrogen receptor concentration and activity by an erbB/HER ligand in breast carcinoma cell lines. Endocrinology, 1996, 137, 4322-4330.	2.8	5
177	Peripheral Blood Mononuclear Cells Predict Therapeutic Efficacy of Immunotherapy in NSCLC. Cancers, 2022, 14, 2898.	3.7	5
178	Gemcitabine plus taxane combinations in metastatic breast cancer:a comprehensive review. European Journal of Cancer, Supplement, 2005, 3, 9-16.	2.2	4
179	P198 Prospective trans-GEICAM study of the impact of the 21-gene recurrence score assay and traditional clinico-pathological factors on clinical decision making in women with estrogen receptor-positive, HER2-negative, node-negative breast cancer. Breast, 2011, 20, S43.	2.2	4
180	A Fatty Acid Synthase Inhibitor Shows New Anticancer Mechanisms. EBioMedicine, 2015, 2, 778-779.	6.1	4

#	ARTICLE	IF	CITATIONS
181	Epigenetic Regulation of Gfi1 in Endocrine-Related Cancers: A Role Regulating Tumor Growth. International Journal of Molecular Sciences, 2020, 21, 4687.	4.1	4
182	Abstract PD4-07: Subcutaneous administration of the fixed-dose combination of trastuzumab and pertuzumab in combination with chemotherapy in HER2-positive early breast cancer: Primary analysis of the phase III, multicenter, randomized, open-label, two-arm FeDeriCa study. , 2020, , .		4
183	BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study. Journal of Patient-Reported Outcomes, 2019, 3, 72.	1.9	4
184	Antiangiogenics and Hypoxic Response: Role of Fatty Acid Synthase Inhibitors. Current Drug Targets, 2016, 17, 1735-1746.	2.1	4
185	Serum CA 15.3 levels in patients with general pathology and malignant diseases (excluding breast) Tj ETQq1 1 0.784314 rgBT /Overlook	1.6	4
186	High-dose mitoxantrone and cyclophosphamide without stem cell support in high-risk and advanced solid tumors: a phase I trial. Bone Marrow Transplantation, 2001, 27, 117-123.	2.4	3
187	Does HER-2 Status Predict Only a Decreased Response to Hormone Therapy in Advanced Breast Cancer, or Does It Also Predict the Extent of Metastatic Disease?. Journal of Clinical Oncology, 2002, 20, 4605-4606.	1.6	3
188	Current controversies in the management of early breast cancer. Clinical and Translational Oncology, 2007, 9, 375-84.	2.4	3
189	Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients. Clinical and Translational Oncology, 2009, 11, 727-736.	2.4	3
190	Selective activity over a constitutively active RETâ€variant of the oral multikinase inhibitor dicitinib: Results of the CNIOâ€BR002 phase Iâ€trial. Molecular Oncology, 2014, 8, 1719-1728.	4.6	3
191	Dermatofibrosarcoma Protu-Berans with Lung Metastasis Requiring Pneumonectomy. Rare Tumors, 2015, 7, 166-168.	0.6	3
192	43O Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial. Annals of Oncology, 2021, 32, S38-S39.	1.2	3
193	Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib + paclitaxel vs trastuzumab + paclitaxel as first-line treatment for HER2+ metastatic breast cancer (NEfERTT).. Journal of Clinical Oncology, 2015, 33, 610-610.	1.6	3
194	Standard versus high-dose therapy in 10+ breast cancer.. Journal of Clinical Oncology, 1998, 16, 810-811.	1.6	2
195	Dietary interventions in cancer. Clinical and Translational Oncology, 2004, 6, 496-500.	2.4	2
196	Dose and Dose Intensity Effect of Adjuvant Anthracycline-Based Chemotherapy in Early Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 269-273.	1.3	2
197	Current controversies in the management of breast cancer. Clinical and Translational Oncology, 2010, 12, 278-286.	2.4	2
198	Prediction of Response to Targeted Therapies in Lung Cancer Using Dynamic Imaging: Still Far From Clinical Implementation. Journal of Clinical Oncology, 2011, 29, 3716-3718.	1.6	2

#	ARTICLE	IF	CITATIONS
199	Is Metastatic Disease the Best Setting for Cost-Effectiveness Studies?. Journal of Clinical Oncology, 2016, 34, 3226-3227.	1.6	2
200	Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer patients. Journal of Clinical Oncology, 2004, 22, 507-507.	1.6	2
201	Microarray gene expression analysis of fatty acid synthase (FAS) signaling on breast cancer cell lines. Journal of Clinical Oncology, 2004, 22, 9690-9690.	1.6	2
202	Dovitinib lactate. Drugs of the Future, 2013, 38, 81.	0.1	2
203	Validation of a new questionnaire to assess the patient perception of cancer-related fatigue (CRF): The Perform Questionnaire (PQ). Journal of Clinical Oncology, 2007, 25, 19533-19533.	1.6	2
204	Should prophylactic surgery be used in women with a high risk of breast cancer?. European Journal of Cancer, 1997, 33, 2158-2159.	2.8	1
205	Combined treatment with biphosphonates, low-dose chemotherapy, and trastuzumab in receptor-negative breast cancer patients with bone marrow involvement. European Journal of Internal Medicine, 2001, 12, 462-463.	2.2	1
206	554 POSTER The mTOR effector p70 S6 kinase 1 (S6K1): a specific biomarker for the biological effects of the dual HER1/HER2 kinase inhibitor Lapatinib (GW572016) in HER2-overexpressing breast cancer cells. European Journal of Cancer, Supplement, 2006, 4, 168.	2.2	1
207	2105 POSTER An accelerated loading regimen for trastuzumab leads to early higher than steady-state serum concentrations. European Journal of Cancer, Supplement, 2007, 5, 215.	2.2	1
208	Review of gemcitabine plus taxane combination therapy in the first-line treatment of metastatic breast cancer. European Journal of Cancer, Supplement, 2008, 6, 9-12.	2.2	1
209	Congress of the Spanish Society of Medical Oncology (SEOM) in Barcelona. Clinical and Translational Oncology, 2009, 11, 707-707.	2.4	1
210	Estimated Costs of Locoregional and Metastatic Recurrences in Patients with HER2+ Breast Cancer in Spain. Value in Health, 2016, 19, A729.	0.3	1
211	Treatment Rates in Patients with HER2+ Metastatic Breast Cancer and the Factors Influencing Treatment Decision. Value in Health, 2016, 19, A764-A765.	0.3	1
212	Nivolumab-induced thyroid dysfunction in patients with lung cancer. Endocrinología y Nutrición (English Ed), 2019, 66, 26-34.	0.2	1
213	Abstract P4-21-41: Primary analysis of BERENICE: A phase II cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with locally advanced, inflammatory, or early-stage, unilateral, and invasive HER2-positive breast cancer. , 2017, , .		1
214	Access to specialized cancer care and clinical trials for cancer patients from non-urban areas is facilitated by a Cancer Network organization. Journal of Clinical Oncology, 2006, 24, 16006-16006.	1.6	1
215	PCN78 Costs of Recurrence in Patients with HER2+ Breast Cancer in Spain. Value in Health, 2020, 23, S435.	0.3	1
216	Dose intensity and clinical response in head and neck carcinoma treated with cisplatin + 5-fluorouracil. , 2002, 4, 485-490.		1

#	ARTICLE	IF	CITATIONS
217	Meningioma preceding breast cancer. <i>Cancer Treatment Reports</i> , 1987, 71, 550-1.	0.5	1
218	Correspondence re: S. Shimoyama et al., increased serum angiogenin concentration in colorectal cancer is correlated with cancer progression. <i>Clin. Cancer Res.</i> , 5: 1125-1130, 1999. <i>Clinical Cancer Research</i> , 1999, 5, 3722-3.	7.0	1
219	Circulating antigen levels in ovarian cancer.. <i>Journal of Clinical Oncology</i> , 1986, 4, 1148-1149.	1.6	0
220	A decade of clinical investigation in elderly patients with non-Hodgkin's lymphoma: Results as reported in the literature. <i>European Journal of Cancer</i> , 1997, 33, S266-S267.	2.8	0
221	Favourable prognosis after late relapse in Hodgkin's disease. <i>European Journal of Cancer</i> , 1997, 33, S263.	2.8	0
222	Cancer care in rural areas. <i>British Journal of Cancer</i> , 2004, 90, 1688-1688.	6.4	0
223	Management of metastatic breast cancer: are we prepared to cope with our own success?. <i>British Journal of Cancer</i> , 2004, 91, 2101-2101.	6.4	0
224	Gemcitabine- and taxane-based protocols in breast cancer. <i>American Journal of Cancer</i> , 2004, 3, 19-20.	0.4	0
225	Growth and Molecular Interactions between Tamoxifen and Trastuzumab. <i>Clinical Cancer Research</i> , 2005, 11, 3597-3597.	7.0	0
226	Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer. <i>Breast Cancer Research</i> , 2005, 7, 1.	5.0	0
227	CN2 USING PSYCHOMETRIC AND CLINIMETRIC TECHNIQUES TO SELECT ITEMS FOR USE IN A NEW INSTRUMENT TO MEASURE CANCER-RELATED FATIGUE. <i>Value in Health</i> , 2006, 9, A203.	0.3	0
228	728 POSTER Differential inhibitory effects of epigallocatechin-3-gallate (EGCG) and C75 in cancer fatty acid metabolism. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 115.	2.2	0
229	PCN68 SENSITIVITY TO CHANGE OF THE PERFORM QUESTIONNAIRE (PQ) IN CANCER PATIENTS REPORTING IMPROVEMENT OR DETERIORATION OF THEIR CANCER-RELATED FATIGUE. <i>Value in Health</i> , 2007, 10, A343-A344.	0.3	0
230	An easy, rapid and objective mathematical method to identify fatty acid synthase (oncogenic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 227 10, 219-226.	2.4	0
231	PCN83 PERFORMANCE AND ADEQUACY OF PATIENT-PERSPECTIVE CRITERIA IN THE ASSESSMENT OF TEST-RETEST RELIABILITY: THE CASE OF THE PERFORM QUESTIONNAIRE. <i>Value in Health</i> , 2008, 11, A486.	0.3	0
232	A new multidisciplinary Spanish Working Group on Cancer Biomarkers: presentation and aims. <i>Clinical and Translational Oncology</i> , 2012, 14, 323-324.	2.4	0
233	269 Molecular interplay between cancer cell fatty acid metabolism and oncogenic signaling as resource for novel treatment strategies against ovarian cancer. <i>European Journal of Cancer</i> , 2015, 51, S49.	2.8	0
234	Cost-Utility Analysis of Neoadjuvant Chemotherapy with Pertuzumab, Trastuzumab and Docetaxel in Patients With HER2+ Breast Cancer in Spain. <i>Value in Health</i> , 2016, 19, A740.	0.3	0

#	ARTICLE	IF	CITATIONS
235	Response to Targeted Therapy and Healthcare Resource Utilization (HRU): A European Retrospective Chart Review Study in Patients With HER2+ Metastatic Breast Cancer. Value in Health, 2016, 19, A742.	0.3	0
236	Exploiting cross-talk between lipid metabolism and oncogenic signaling for treatment of ovarian cancer. European Journal of Cancer, 2016, 61, S61.	2.8	0
237	P1.01-057 Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2017, 12, S1916-S1917.	1.1	0
238	Could a systemic inflammation response index (SIRI) predict overall survival (OS) in metastatic pancreatic cancer (PC)?. Annals of Oncology, 2017, 28, v30-v31.	1.2	0
239	Safety of self-expandable metal stents (SEMS) or emergency surgery for acute colonic obstruction in metastatic colon cancer patients treated with bevacizumab. Annals of Oncology, 2018, 29, v97.	1.2	0
240	PCN20 - CONTRIBUTION OF TRASTUZUMAB TO THE PROGNOSTIC IMPROVEMENT OF HER2-POSITIVE EARLY BREAST CANCER IN SPAIN. Value in Health, 2018, 21, S18.	0.3	0
241	The impact of primary tumor location in patients with resected colorectal liver metastasis. Annals of Oncology, 2018, 29, v79.	1.2	0
242	46P Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Safety results from the adjuvant phase of the randomised, open-label, multicentre phase III (neo)adjuvant FeDeriCa study. Annals of Oncology, 2021, 32, S40-S41.	1.2	0
243	1287P Immune T-cell subpopulations from the peripheral blood of non-small cell lung cancer patients are associated with the efficacy of anti-PD-1 immunotherapy. Annals of Oncology, 2021, 32, S999-S1000.	1.2	0
244	Determining the clinical significance of the improvement in health-related quality of life (HRQoL) measures in oncology patients. Journal of Clinical Oncology, 2008, 26, 20622-20622.	1.6	0
245	MG28, a novel fatty acid synthase inhibitor, overcomes resistance to anti-HER therapies in breast cancer.. , 2009, , .		0
246	Relationship of breast cancer stem cells (CSCs) and chronic O ₂ /glucose deprivation (C-OGD).. Journal of Clinical Oncology, 2010, 28, 10509-10509.	1.6	0
247	Prevalence and management of anemia in patients with non-myeloid tumors undergoing systemic therapy.. Journal of Clinical Oncology, 2010, 28, e19658-e19658.	1.6	0
248	Abstract PD5-8: Phase I clinical trial of neoadjuvant BIBF1120 plus weekly paclitaxel (P) in early HER-2 negative breast cancer. CNIO-BR-01-2010/GEICAM 2010-10 study. , 2013, , .		0
249	Abstract P3-10-02: The BOMET-QOL questionnaire in patients with breast cancer and bone metastasis: The prospective MABOMET study from the Spanish breast cancer research group (GEICAM). , 2013, , .		0
250	Abstract 1493: 18F-misonidazole PET (FMISO-PET) monitors vascular normalization (VN) and predicts benefit from antiangiogenic treatment plus chemotherapy in pancreas cancer. , 2015, , .		0
251	Phase I trial of the combination of the multikinase inhibitor nintedanib plus letrozole: A window of opportunity trial in adjuvant hormone-receptor positive breast cancer (HRPBC).. Journal of Clinical Oncology, 2016, 34, TPS615-TPS615.	1.6	0
252	Abstract P3-12-05: Estimating costs of relapsing HER2+ breast cancer in Spain. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
253	Abstract P3-12-02: Cost-effectiveness analysis of adding neoadjuvant chemotherapy with pertuzumab, in patients with HER2+ breast cancer in Spain. , 2017, , .		0
254	Safety of self-expandable metal stents (SEMS) or emergency surgery for acute malignant colonic obstruction in patients treated with bevacizumab.. Journal of Clinical Oncology, 2018, 36, e15505-e15505.	1.6	0
255	Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approval. Oncotarget, 2019, 10, 4321-4332.	1.8	0
256	PCN110 Cost-Utility Analysis of Adjuvant Trastuzumab Emtansine Versus Trastuzumab in Patients with HER2+ EARLY Breast Cancer with Residual Invasive Disease after Neoadjuvant Therapy in Spain. Value in Health, 2020, 23, S442.	0.3	0
257	Effects of dietary fatty acids on the proliferation, adhesion and metastatic potential of breast cancer cells: an experimental review. , 2002, 4, 77-84.		0
258	Gemcitabine, paclitaxel plus trastuzumab (GTH) in HER2 ECD-positive metastatic breast cancer. Journal of Clinical Oncology, 2004, 22, 740-740.	1.6	0